# NCT03768570 (NCT03768570)

> Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03768570
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Canadian Cancer Trials Group
- Conditions: Bladder Cancer
- Interventions: Durvalumab
- Enrollment: 82
- Primary outcome: Disease-free survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03768570